E. Krognes - Feb 13, 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role: Director
Signature: /s/ Tyler Nielsen, by power of attorney
Stock symbol: DNLI
Transactions as of: Feb 13, 2023
Transactions value $: -$63,782
Form type: 4
Date filed: 2/15/2023, 06:02 PM
Previous filing: Feb 10, 2023
Next filing: Jun 5, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNLI	Common Stock	Sale	-$63.8K	-2.12K	-1.46%	$30.10	143K	Feb 13, 2023	Direct	F1, F2, F3
holding	DNLI	Common Stock						850K	Feb 13, 2023	See footnote	F4

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2	The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.90 to $30.22 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3	Includes 32,286 RSUs.
F4	The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.